Phase 1 Study of Tazemetostat, An Enhancer of Zeste Homolog-2 (EZH2) Inhibitor, In Pediatric Patients With Relapsed/Refractory Integrase Interactor 1 (INI1)-Negative Tumors

被引：0

作者：

Chi, S. ^{[1
]}

Bourdeaut, F. ^{[2
]}

Laetsch, T. ^{[3
]}

Fouladi, M. ^{[4
]}

Macy, M. ^{[5
]}

Makin, G. ^{[6
]}

Shukla, N. ^{[7
]}

Wetmore, C. ^{[8
]}

Margol, A. ^{[9
]}

Casanova, M. ^{[10
]}

Kilburn, L. ^{[11
]}

Yi, J. ^{[12
,13
]}

Hargrave, D. ^{[14
]}

Mccowage, G. ^{[15
]}

Pinto, N. ^{[16
]}

Ebb, D. ^{[17
]}

Robinson, G. ^{[18
]}

Sierra, L. ^{[19
]}

Merchant, M. ^{[19
]}

Nysom, K. ^{[20
]}

机构：

[1] Dana Farber Canc Inst, Neurooncol, Boston, MA 02115 USA

[2] Curie Inst, Care Innovat Res, Childhood Canc, Adolescents & Young Adults, Paris, France

[3] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA

[4] Cincinnati Childrens Hosp, Canc & Blood Dis, Brain Tumor, Oncol, Cincinnati, OH USA

[5] Childrens Hosp Colorado, Canc & Blood Disorders, Expt Therapeut, Oncol, Aurora, CO USA

[6] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[7] Mem Sloan Kettering Canc Ctr, Pediat Hematol Oncol, 1275 York Ave, New York, NY 10021 USA

[8] Phoenix Childrens Hosp, Hematol & Oncol, Phoenix, AZ USA

[9] Childrens Hosp Los Angeles, Canc & Blood Dis Inst, Los Angeles, CA 90027 USA

[10] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy

[11] Childrens Natl Hosp, Brain Tumor Inst, Ctr Canc & Blood Disorders, Expt Therapeut Program,Oncol,Neurofibromatosis In, Washington, DC USA

[12] Texas Childrens Hosp, Dev Therapeut Phase Clin 1, Leukemia Program, Canc Ctr, Houston, TX 77030 USA

[13] Texas Childrens Hosp, Dev Therapeut Phase Clin 1, Leukemia Program, Hematol Ctr, Houston, TX 77030 USA

[14] Great Ormond St Hosp Sick Children, Dept Haematol & Oncol, London, England

[15] Childrens Hosp Westmead, Canc Ctr Children, Clin Trials, Westmead, NSW, Australia

[16] Seattle Childrens Hosp, Hematol Oncol, Seattle, WA USA

[17] Massachusetts Gen Hosp, Canc Care, Pediat, Boston, MA 02114 USA

[18] St Jude Childrens Res Hosp, Dept Oncol, St Jude Grad Sch Biomed Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[19] Epizyme, Early Stage Dev, Cambridge, MA USA

[20] Rigshosp, Paediat & Adolescent Med, Copenhagen, Denmark

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

0261

引用

页码：S123 / S124

页数：2

共 50 条

[1] Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.
Chi, Susan N.
Bourdeaut, Franck
Laetsch, Theodore Willis
Fouladi, Maryam
Macy, Margaret E.
Makin, Guy W. J.
Shukla, Neerav Narendra
Wetmore, Cynthia
Margol, Ashley S.
Casanova, Michela
Kilburn, Lindsay Baker
Yi, Joanna
Hargrave, Darren R.
McCowage, Geoffrey Brian
Pinto, Navin R.
Ebb, David
Robinson, Giles W.
Sierra, Laura
Merchant, Melinda
Nysom, Karsten
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1-negative tumors.
Chi, Susan N.
Bourdeaut, Franck
Casanova, Michela
Kilburn, Lindsay Baker
Hargrave, Darren R.
McCowage, Geoffrey Brian
Pinto, Navin R.
Yang, Jay
Chadha, Raminder
Kahali, Bhaskar
Tapia, Coya
Nysom, Karsten
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.
Chi, Susan N.
McCowage, Geoffrey Brian
Hoffman, Lindsey
Macy, Margaret
Doleman, Susan
Blakemore, Stephen J.
Clawson, Alicia
Daigle, Scott
Tang, Jeanie
Roche, Maria
Ho, Peter T. C.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] PHASE 1 STUDY OF THE EZH2 INHIBITOR, TAZEMETOSTAT, IN CHILDREN WITH RELAPSED OR REFRACTORY INI1-NEGATIVE TUMORS INCLUDING RHABDOID TUMORS, EPITHELIOID SARCOMA, CHORDOMA; AND SYNOVIAL SARCOMA
Chi, Susan
Fouladi, Maryam
Shukla, Neerav
Bourdeaut, Franck
Margol, Ashley
Makin, Guy
McCowage, Geoff
Wetmore, Cynthia
Macy, Margaret
Laetsch, Ted W.
Hargrave, Darren
Pinto, Navin
Yi, Joanna
Ebb, Dave
Robinson, Giles
Roche, Maria
Suttle, Benjamin
Clawson, Alicia
Ho, Peter
Rodstrom, Jill
Daigle, Scott
Nysom, Karsten
PEDIATRIC BLOOD & CANCER, 2018, 65
[5] Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma
Chi, Susan
Fouladi, Maryam
Shukla, Neerav
Bourdeaut, Franck
Margol, Ashley
Makin, Guy
McCowage, Geoff
Wetmore, Cynthia
Macy, Margaret
Laetsch, Ted
Hargrave, Darren
Pinto, Navin
Yi, Joanna
Ebb, Dave
Robinson, Giles
Roche, Maria
Suttle, Benjamin
Clawson, Alicia
Ho, Peter
Rodstrom, Jill
Daigle, Scott
Nysom, Karsten
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[6] A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.
Agulnik, Mark
Tannir, Nizar M.
Pressey, Joseph Gerald
Gounder, Mrinal M.
Cote, Gregory Michael
Roche, Maria
Doleman, Susan
Blakemore, Stephen J.
Clawson, Alicia
Daigle, Scott
Tang, Jeanie
Ho, Peter T. C.
Demetri, George D.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors
Italiano, A.
Keilhack, H.
Toulmonde, M.
Coindre, J. M.
Michot, J. M.
Massard, C.
Ottesen, L.
Reyderman, L.
Blakemore, S. J.
Kraljevic, S.
Thomson, B.
McDonald, A.
Ho, P. T.
Ribrag, V.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S55
[8] Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non Hodgkin Lymphoma (NHL) Patients
Ribrag, Vincent
Soria, Jean-Charles
Michot, Jean-Marie
Schmitt, Anna
Postel-Vinay, Sophie
Bijou, Fontanet
Thomson, Blythe
Keilhack, Heike
Blakemore, Stephen J.
Reyderman, Larisa
Kumar, Pavan
Fine, Greg
McDonald, Alice
Ho, Peter T.
Italiano, Antoine
BLOOD, 2015, 126 (23)
[9] A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)
Stacchiotti, S.
Blay, J-Y.
Jones, R. L.
Demetri, G. D. D.
Mir, O.
Italiano, A.
Thomas, D.
Chen, T. W-W.
Schoffski, P.
Gil, T.
Jahan, T.
Cote, G.
Ratan, R.
Attia, S.
Roche, M.
Daigle, S.
Sapir, I.
Clawson, A.
Gounder, M.
ANNALS OF ONCOLOGY, 2018, 29 : 580 - 580
[10] Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
Morschhauser, Franck
Tilly, Herve
Chaidos, Aristeidis
Phillips, Tycel J.
Ribrag, Vincent
Campbell, Philip
Laurent, Damaj Gandhi
Jurczak, Wojciech
McKay, Pamela
Opat, Stephen
Radford, John
Whalen, Jennifer
Rajarethinam, Anand
Navia, Susan Benedict
Adib, Deyaa
Salles, Gilles
BLOOD, 2019, 134

← 1 2 3 4 5 →